MicroRNA 802: A Potential Drug Target and Diagnostic Tool (G768219)
MicroRNA 802: A Potential Drug Target and Diagnostic Tool
MicroRNA (miRNA) 802 is a non-coding RNA molecule that plays a critical role in regulating various cellular processes in humans. It is composed of 204 amino acid residues and has a calculated molecular weight of 23.1 kDa. MIR802 is expressed in various tissues and cells of the human body, including the brain, heart, and peripheral tissues. It is a potent regulator of gene expression and has been implicated in the development and progression of various diseases, including cancer.
MIR802 has been shown to play a key role in regulating the expression of genes involved in cell adhesion, migration, and invasion. It has been shown to promote the expression of genes involved in the development of brain tumors, including neuroblastoma and astrocytoma. MIR802 has also been shown to contribute to the development of various cardiovascular diseases, including myocardial infarction and hypertension.
In addition to its role in disease, MIR802 has also been shown to have potential as a drug target or biomarker. Several studies have suggested that MIR802 may be a potential drug target for the treatment of various diseases, including cancer, cardiovascular disease, and neurodegenerative diseases.
One potential mechanism by which MIR802 may be targeted by drugs is through its role in regulating the expression of genes involved in cell signaling pathways. MIR802 has been shown to play a role in the regulation of several signaling pathways, including the TGF-β pathway and the Wnt pathway. These signaling pathways are involved in the regulation of cellular processes such as cell growth, differentiation, and survival. By targeting MIR802, drugs may be able to disrupt these signaling pathways and prevent the development or progression of various diseases.
Another potential mechanism by which MIR802 may be targeted by drugs is through its role in regulating the expression of genes involved in inflammation. MIR802 has been shown to play a role in the regulation of several processes involved in inflammation, including the production of pro-inflammatory cytokines and the recruitment of immune cells to sites of inflammation. These processes are involved in the development and progression of various inflammatory diseases, including cancer and cardiovascular disease. By targeting MIR802, drugs may be able to disrupt these processes and prevent the development or progression of these diseases.
In addition to its potential as a drug target or biomarker, MIR802 has also been shown to have potential as a diagnostic tool. Several studies have suggested that MIR802 may be a potential biomarker for the diagnosis of various diseases, including cancer, neurodegenerative diseases, and cardiovascular disease. This is because MIR802 has been shown to be expressed in these diseases and may be able to serve as a diagnostic target for these conditions.
Overall, MIR802 is a microRNA that has been shown to play a critical role in regulating various cellular processes in the human body. Its potential as a drug target or biomarker makes it an attractive target for the development of new therapies for the treatment of various diseases. Further research is needed to fully understand the role of MIR802 in disease and its potential as a diagnostic tool.
Protein Name: MicroRNA 802
The "MIR802 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR802 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR8054 | MIR8055 | MIR8059 | MIR8060 | MIR8061 | MIR8063 | MIR8064 | MIR8067 | MIR8069-1 | MIR8070 | MIR8071-1 | MIR8071-2 | MIR8072 | MIR8073 | MIR8075 | MIR8076 | MIR8078 | MIR8080 | MIR8082 | MIR8084 | MIR8085 | MIR8087 | MIR8088 | MIR8089 | MIR8485 | MIR873 | MIR874 | MIR875 | MIR876 | MIR877 | MIR885 | MIR887 | MIR888 | MIR889 | MIR890 | MIR891A | MIR891B | MIR892A | MIR892B | MIR892C | MIR9-1 | MIR9-1HG | MIR9-2 | MIR9-3 | MIR9-3HG | MIR920 | MIR921 | MIR922 | MIR924 | MIR924HG | MIR92A1 | MIR92A2 | MIR92B | MIR93 | MIR933 | MIR934 | MIR935 | MIR936 | MIR937 | MIR938 | MIR939 | MIR940 | MIR941-1 | MIR941-2 | MIR941-3 | MIR941-4 | MIR941-5 | MIR942 | MIR943 | MIR944 | MIR95 | MIR96 | MIR98 | MIR99A | MIR99AHG | MIR99B | MIRLET7 | MIRLET7A1 | MIRLET7A2 | MIRLET7A3 | MIRLET7B | MIRLET7BHG | MIRLET7C | MIRLET7D | MIRLET7E | MIRLET7F1 | MIRLET7F2 | MIRLET7G | MIRLET7I | MIS12 | MIS12 complex | MIS18A | MIS18A-AS1 | MIS18BP1 | MISFA | MISP | MISP3 | MITD1 | MITF | Mitochondrial complex I assembly complex
